全文获取类型
收费全文 | 4798篇 |
免费 | 361篇 |
国内免费 | 18篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 189篇 |
妇产科学 | 7篇 |
基础医学 | 274篇 |
口腔科学 | 17篇 |
临床医学 | 154篇 |
内科学 | 3394篇 |
皮肤病学 | 64篇 |
神经病学 | 30篇 |
特种医学 | 22篇 |
外科学 | 31篇 |
综合类 | 77篇 |
预防医学 | 53篇 |
眼科学 | 14篇 |
药学 | 158篇 |
中国医学 | 11篇 |
肿瘤学 | 680篇 |
出版年
2023年 | 90篇 |
2022年 | 24篇 |
2021年 | 54篇 |
2020年 | 138篇 |
2019年 | 133篇 |
2018年 | 123篇 |
2017年 | 127篇 |
2016年 | 153篇 |
2015年 | 152篇 |
2014年 | 185篇 |
2013年 | 243篇 |
2012年 | 154篇 |
2011年 | 192篇 |
2010年 | 178篇 |
2009年 | 192篇 |
2008年 | 187篇 |
2007年 | 210篇 |
2006年 | 160篇 |
2005年 | 170篇 |
2004年 | 147篇 |
2003年 | 170篇 |
2002年 | 181篇 |
2001年 | 167篇 |
2000年 | 173篇 |
1999年 | 119篇 |
1998年 | 116篇 |
1997年 | 136篇 |
1996年 | 143篇 |
1995年 | 138篇 |
1994年 | 106篇 |
1993年 | 43篇 |
1992年 | 44篇 |
1991年 | 46篇 |
1990年 | 35篇 |
1989年 | 33篇 |
1988年 | 36篇 |
1987年 | 36篇 |
1986年 | 20篇 |
1985年 | 80篇 |
1984年 | 32篇 |
1983年 | 30篇 |
1982年 | 37篇 |
1981年 | 46篇 |
1980年 | 32篇 |
1979年 | 42篇 |
1978年 | 37篇 |
1977年 | 31篇 |
1976年 | 19篇 |
1975年 | 17篇 |
1971年 | 4篇 |
排序方式: 共有5177条查询结果,搜索用时 15 毫秒
151.
Josu de la Fuente Andr Baruchel Andrea Biondi Eveline de Bont Marie‐Franoise Dresse Meinolf Suttorp Frdric Millot 《British journal of haematology》2014,167(1):33-47
Chronic myeloid leukaemia in children and young people is a relatively rare form of leukaemia that shows increased incidence with age and some evidence suggests that the molecular basis differs from that in adults. Significant advances in targeted therapy with the development and use in children of tyrosine kinase inhibitors and the ability to monitor and understand the prognostic significance of minimal residual disease by standardized molecular techniques has shifted the management of this condition from bone marrow transplantation as the main therapeutic modality to individualized treatment for each patient based on achieving specific milestones. The physiological changes occurring during childhood, particularly those affecting growth and development and the long‐term use of treatment, pose specific challenges in this age group, which we are only beginning to understand. 相似文献
152.
Yuko Honda Masahiro Tsuchida Yuji Zaike Atsuko Masunaga Ayami Yoshimi Seiji Kojima Masafumi Ito Akira Kikuchi Tatsutoshi Nakahata Atsushi Manabe 《British journal of haematology》2014,165(5):682-687
Juvenile myelomonocytic leukaemia (JMML) is a rare haematopoietic stem cell disease of early childhood, which can progress to blast crisis in some children. A total of 153 children diagnosed with JMML were reported to the Myelodysplastic Syndrome Committee in Japan between 1989 and 2007; 15 of them (9·8%) had 20% or more blasts in the bone marrow (blast crisis) during the disease course. Blast crisis occurred during observation without therapy (n = 3) or with oral 6‐mercaptopurine treatment (n = 9) and in relapse after haematopoietic stem cell transplantation (HSCT; n = 3). Six patients had a complex karyotype (5 including monosomy 7) and an additional three patients had isolated monosomy 7 at blast crisis. Seven patients received HSCT after blast crisis and four of them achieved remission. Eleven out of the 15 patients died; the cause of death was disease progression in 10 patients and transplant‐related complication in one patient. In summary, patients with blast crisis have poor prognosis and can be cured only by HSCT. The emergence of monosomy 7 and complex karyotype may be characteristic of blast crisis in a substantial subset of children. 相似文献
153.
Alexandra Spiegel Catherine Paillard Stephane Ducassou Yves Perel Dominique Plantaz Marion Strullu Alice Eischen Patrick Lutz Laurence Lamant Marie‐Cécile Le Deley Laurence Brugières 《British journal of haematology》2014,165(4):545-551
This study aimed to describe the clinical features and outcome of anaplastic large cell lymphoma (ALCL) with leukaemic presentation in children. Among 267 patients included in the French paediatric ALCL database between 1989 and 2012, nine (3%) were described as having cytologically detectable circulating tumour cells. Clinical features combined fever (8/9), nodal and extra‐nodal disease (9/9), including hepato‐splenic (9/9) and lung involvement (7/9). The level of hyperleucocytosis ranged from 30 to 120 × 109/l, with 12–90% of tumour cells. Diagnosis relied on a lymph node biopsy, with a positive ALK+ antibody immunostain in all nine cases, a T‐cell immunophenotype in 7/9 cases and CD3 positivity in 5/9 cases. A small cell component was present in 6/9 cases. Only four patients achieved a complete remission with first‐line therapy and 3/4 relapsed. Four patients are alive with a median follow‐up of 31 months, two of them after allogeneic haematopoietic stem cell transplantation (HSCT), and five patients died, two of them of disease. In conclusion, ALCL with leukaemic presentation is very unusual and should be considered as high‐risk lymphoma requiring new therapeutic strategies. The respective role of new agents and allogeneic HSCT in first complete remission still has to be assessed. 相似文献
154.
155.
Anne‐Lise Alloin Vincent Barlogis Pascal Auquier Audrey Contet Maryline Poiree François Demeocq Iris Herrmann Virginie Villes Yves Bertrand Dominique Plantaz Justyna Kanold Pascal Chastagner Hervé Chambost Nicolas Sirvent Gérard Michel 《British journal of haematology》2014,164(1):94-100
Corticosteroid and central nervous system (CNS) irradiation can induce cataract in childhood lymphoblastic leukaemia survivors. Few prospective studies with systematic ophthalmological evaluation have been published. Cataract was prospectively assessed by serial slip lamp tests in 517 patients. All had acute lymphoblastic leukaemia, all had been treated by chemotherapy with or without CNS irradiation, and none had received haematopoietic stem cell transplantation. Median ages at last evaluation and follow‐up duration from leukaemia diagnosis were 16·8 and 10·9 years, respectively. Cataract was observed in 21/517 patients (4·1%). Cumulative incidence was 4·5 ± 1·2% at 15 years and reached 26 ± 8·1% at 25 years. CNS irradiation was the only risk factor: prevalence was 11·1% in patients who had received irradiation and 2·8% in those who did not. We did not detect any steroid dose effect: cumulative dose was 5133 and 5190 mg/m2 in patients with and without cataract, respectively. Cataract occurrence did not significantly impact quality of life. We conclude that, in the range of steroid dose reported here, the cataract risk proves very low 15 years after treatment without CNS irradiation but an even more prolonged follow‐up is required because of potential very late occurrence. 相似文献
156.
A consistent pattern of response has been observed when FMS‐like tyrosine kinase 3 (FLT3) tyrosine kinase inhibitors (TKIs) have been used as monotherapy to treat patients with relapsed or refractory FLT3‐ internal tandem duplication (ITD) acute myeloid leukaemia (AML). Circulating blasts are cleared from the peripheral blood, while bone marrow blasts are either unaffected or are cleared from the marrow at a much slower rate. We used an in vitro model of FLT3‐ITD AML blasts co‐cultured with normal human bone marrow stromal cells to investigate the basis for this dichotomous response pattern to FLT3 inhibitors. We have found that in blasts on stroma, potent FLT3 inhibition predominantly results in cell cycle arrest rather than apoptosis. The anti‐apoptotic effect is mediated through a combination of direct cell‐cell contact and soluble factors. The addition of exogenous FLT3 ligand (FL) augments the protection, primarily by shifting the 50% inhibitory concentration for FLT3 inhibition upwards. Cytokine‐activated extracellular regulated kinase (ERK), rather than STAT5, appears to be the most important downstream signalling protein mediating the protective effect, and inhibition of MEK significantly abrogates stromal‐mediated resistance. These findings explain the phenomenon of peripheral blood versus bone marrow blast responses and suggest that the combination of potent FLT3 inhibition and MEK inhibition is a promising strategy for the treatment of FLT3‐ITD AML. 相似文献
157.
Wolfgang Kern Ulrike Bacher Susanne Schnittger Frank Dicker Tamara Alpermann Torsten Haferlach Claudia Haferlach 《British journal of haematology》2014,164(4):565-569
Multiparameter flow cytometry (MFC) identifies rare cases of biclonal disease in chronic lymphocytic leukaemia (CLL). By MFC, we identified 76 patients with biclonal disease in a cohort of 5523 CLL patients (1·4%). Fluorescence in situ hybridization and chromosome banding analysis revealed five and six cases, respectively, with two different cytogenetic aberrations due to clonal evolution. Two different B‐cell receptor rearrangements and IGHV subtypes were more frequent in biclonal than in monoclonal CLL by MFC (37·1% vs. 2·7%; P < 0·001). Patients with biclonal CLL by MFC showed a trend to a shorter time to treatment than monoclonal CLL (P = 0·080). 相似文献
158.
Sue Manley Russell Keenan Helen Campbell Mark Caswell Barry Pizer 《British journal of haematology》2014,164(3):462-464
159.
160.
Håkon Reikvam Jerome Tamburini Silje Skrede Rita Holdhus Laury Poulain Elisabeth Ersvær Kimberley J. Hatfield Øystein Bruserud 《British journal of haematology》2014,164(2):200-211
Acute myeloid leukaemia (AML) is a heterogeneous malignancy. Intracellular signalling through the phosphatidylinositol 3‐kinase (PI3K)‐Akt‐mammalian target of rapamycin (mTOR) pathway is important for regulation of cellular growth and metabolism, and inhibitors of this pathway is considered for AML treatment. Primary human AML cells, derived from 96 consecutive adult patients, were examined. The effects of two mTOR inhibitors (rapamycin, temsirolimus) and two PI3K inhibitors (GDC‐0941, 3‐methyladenine) were studied, and we investigated cytokine‐dependent proliferation, regulation of apoptosis and global gene expression profiles. Only a subset of patients demonstrated strong antiproliferative effects of PI3K‐mTOR inhibitors. Unsupervised hierarchical clustering analysis identified two main clusters of patients; one subset showing weak or absent antiproliferative effects (59%) and another group showing a strong growth inhibition for all drugs and concentrations examined (41%). Global gene expression analyses showed that patients with AML cell resistance against PI3K‐mTOR inhibitors showed increased mRNA expression of the CDC25B gene that encodes the cell cycle regulator Cell Division Cycle 25B. The antileukaemic effect of PI3K‐Akt‐mTOR inhibition varies between patients, and resistance to these inhibitors is associated with the expression of the cell cycle regulator CDC25B, which is known to crosstalk with the PI3K‐Akt‐mTOR pathway and mediate rapamycin resistance in experimental models. 相似文献